ERBB2 and breast cancer: Based on gene expression profiling, breast cancer has been characterized into Luminal A, Luminal B, HER2 (human epidermal growth factor receptor 2)-enriched, and basal-like subtypes—each of which has been shown to have different prognoses [1,2,3,4].